|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Tuscaloosa Research & Education Advancement Corporation |
|---|---|
| Information provided by: | Tuscaloosa Research & Education Advancement Corporation |
| ClinicalTrials.gov Identifier: | NCT00233467 |
Purpose
The main purpose is to show the percentage of patients taking antipsychotics with PTSD by looking at approximately ten year’s worth of data from 1994 through 2004. We will also determine the type and dose of antipsychotics the patients received, and to determine how many of those patients had psychotic versus nonpsychotic symptoms. We will be obtaining this data from the VISN 7 Corporate Data Warehouse. We hypothesize that there has been an overall increase in antipsychotic use in patient’s with PTSD over the last 10 years.
| Condition |
|---|
|
PTSD Posttraumatic Stress Disorder |
| Study Type: | Observational |
| Study Design: | Natural History, Longitudinal, Defined Population, Retrospective Study |
| Official Title: | Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade |
| Estimated Enrollment: | 30 |
| Study Start Date: | September 2005 |
| Estimated Study Completion Date: | September 2005 |
This study is a retrospective chart review of patients, at the Tuscaloosa VA Medical Center, who were, treated with antipsychotics as monotherapy or adjunctive therapy.
The data will be retrieved from a computerized list of patients treated at the TVAMC for PTSD from 1994-2004 Charts will be reviewed by looking at approximately ten year’s worth of data. Charts will then be examined to determine what type of antipsychotics patients were prescribed, the dose and duration of the antipsychotics, and the presence or absence of documented psychotic symptoms.
Eligibility| Ages Eligible for Study: | 19 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
• None
Contacts and Locations| United States, Alabama | |
| Tuscaloosa VA Medical Center | |
| Tuscaloosa, Alabama, United States, 35404 | |
| Principal Investigator: | Rebecca Seamans, PharmD | Tuscaloosa VA Medical Center |
More Information
| Study ID Numbers: | TREAC Retro PTSD |
| Study First Received: | October 3, 2005 |
| Last Updated: | September 20, 2006 |
| ClinicalTrials.gov Identifier: | NCT00233467 |
| Health Authority: | United States: Food and Drug Administration |
|
antipsychotics PTSD posttraumatic stress disorder |
|
Anxiety Disorders Mental Disorders Stress Disorders, Post-Traumatic Stress Stress Disorders, Traumatic |
|
Pathologic Processes Disease |
